J.P. Morgan Was Back, But Not With A Roar

Biopharma executives and investors descended on San Francisco again, but the numbers seemed fewer, the weather was volatile and the outlook for the sector remained uncertain.  

J.P. Morgan returned amid a deluge of rain • Source: Shutterstock (Shutterstock)

The annual J.P. Morgan Healthcare Conference reunited biopharma investors, executives and stakeholders in San Francisco for the first time since 2020 and while attendees embraced the face-to-face interactions and the chance to be reunited with old colleagues and friends, wariness of COVID-19, heavy downpours and investor sentiment all seemed to weigh on optimism over the course of the meeting.

Regeneron Pharmaceuticals, Inc. CEO Len Schleifer summed up some of that sentiment when he took the stage in a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.